Abcam, ab273852, Human TAGLN knockout HeLa cell line

Size: 1000000Cells / vial
TAGLN KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. Knockout achieved by CRISPR/Cas9 X = 16 bp deletion after Asp40 of the WT protein Frameshift: 100%. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,
Mutation description:Knockout achieved by CRISPR/Cas9 X = 16 bp deletion after Asp40 of the WT protein Frameshift: 100%,
Disease:Adenocarcinoma

Product details:
Recommended control:
Human wild-type HeLa cell line (ab271142). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-TAGLN, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TAGLN also known as Transgelin or SM22-alpha is a protein with a molecular weight of approximately 22 kDa. Structurally it belongs to the calponin family and contains an ACT domain which is critical for its actin-binding ability. It is expressed abundantly in smooth muscle cells where it stabilizes cytoskeletal dynamics by interacting with actin filaments. TAGLN also shows expression in fibroblasts and myofibroblasts supporting structural integrity and cellular movement.
Biological function summary
The regulatory involvement of TAGLN in smooth muscle contraction influences cellular activities essential for vascular function. This protein modulates remodeling and differentiation within smooth muscle cells. It can associate with actin and calponin to form complexes that regulate the stability of cytoskeletal structures ensuring effective cellular responses to mechanical stimuli. By linking signal transduction to cytoskeletal mechanics TAGLN facilitates the maintenance of cell shape and tension.
Pathways
TAGLN plays a role in the regulation of the RhoA/Rho kinase pathway contributing to actin cytoskeleton organization and smooth muscle contraction. Additionally it is involved in the WNT signaling pathway influencing cell proliferation and differentiation. In these pathways TAGLN works with proteins like RhoA and beta-catenin to transmit signals from the extracellular environment to the nucleus impacting gene expression and cellular responses.
Disruptions in TAGLN expression associate with vascular diseases and certain cancers. Downregulation or altered expression patterns can lead to smooth muscle cell dysfunction contributing to atherosclerosis. Similarly TAGLN interacts with proteins such as fibronectin and MMP2 in cancer where its altered expression could promote metastasis and tumor progression. Understanding these connections highlights TAGLN's potential as a target for therapeutic interventions in these diseases.